Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders

Journal of Korean Medical Science

Volumn 25, Issue 4, 2010, Pages 523-526

  Choi, Jung Hye ^a   Park, Byeong Bae ^a   Suh, Cheolwon ^b   Won, Jong Ho ^c   Lee, Won Sik ^d   Shin, Ho Jin ^e  

^a Hanyang University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Pusan National University School of Medicine   (South Korea)

Author keywords

Monomorphic post transplant lymphoproliferative disorders

Indexed keywords

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLASSIFICATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; HUMAN; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISEASE; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954014026     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.4.523     Document Type: Article

References (11)

1. LaCasce AS. Post-transplant lymphoproliferative disorders. Oncologist 2006; 11: 674-80.
2. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
3. Swerdlow SH, Webber SA, Chadburn A, Ferry JA. Post-transplant lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Sterin H, Thiele J, Vardiman JW, editors, The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues. Lyon: IARC 2008; 343-9.
4. Buadi FK, Heyman MR, Gocke CD, Rapoport AP, Hakimian R, Bartlett ST, Sarkodee-Adoo C. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol 2007; 82: 208-14.
5. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005; 79: 244-7.
6. Lee JJ, Joo DJ, Kim SJ, Huh KH, Ju MK, Kim MS, Kim SI, Kim YS. Posttransplant lymphoproliferative disorders in kidney transplant patients: report from a single-center over 25 years. J Korean Soc Transplant 2008; 22: 226-31.
7. Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY, Tien HF, Chang HH, Lu MY, Lin TT, Lin KH, Hsiao CH, Lin CW, Chen YC. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009; 43: 315-21.
8. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715-22.
9. Chang MS, Kim WH. Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma. Cancer Res Treat 2005; 37: 257-67.
10. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, Gandjbakhch I, Binet JL, Raphael M. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16: 2052-9.
11. Nelson BP, Nalesnik MA, Bahler DW, Locker J, Fung JJ, Swerdlow SH. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000; 24: 375-85.